Pacira Pharmaceuticals (NASDAQ:PCRX) had its price objective lifted by HC Wainwright to $60.00 in a research note issued to investors on Friday, The Fly reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target would suggest a potential upside of 19.24% from the stock’s current price.

Several other research firms have also weighed in on PCRX. Canaccord Genuity set a $45.00 target price on shares of Pacira Pharmaceuticals and gave the company a “hold” rating in a research note on Tuesday, September 4th. Wedbush reiterated an “outperform” rating and set a $80.00 target price (down previously from $85.00) on shares of Pacira Pharmaceuticals in a research note on Monday, August 6th. ValuEngine upgraded shares of Pacira Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, October 18th. Cowen reiterated a “hold” rating on shares of Pacira Pharmaceuticals in a research note on Tuesday, July 10th. Finally, Piper Jaffray Companies set a $48.00 target price on shares of Pacira Pharmaceuticals and gave the company a “buy” rating in a research note on Thursday, August 2nd. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and ten have assigned a buy rating to the stock. Pacira Pharmaceuticals has a consensus rating of “Hold” and an average target price of $51.56.

PCRX stock opened at $50.32 on Friday. The company has a debt-to-equity ratio of 0.98, a current ratio of 8.58 and a quick ratio of 7.79. Pacira Pharmaceuticals has a 1-year low of $26.95 and a 1-year high of $55.00. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of 279.56 and a beta of 1.68.

Pacira Pharmaceuticals (NASDAQ:PCRX) last released its earnings results on Thursday, November 1st. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.40. Pacira Pharmaceuticals had a negative net margin of 1.30% and a positive return on equity of 2.79%. The firm had revenue of $83.45 million during the quarter, compared to analyst estimates of $79.87 million. During the same quarter in the previous year, the firm earned $0.11 earnings per share. The firm’s revenue for the quarter was up 23.9% compared to the same quarter last year. Equities research analysts predict that Pacira Pharmaceuticals will post -0.21 earnings per share for the current fiscal year.

In related news, CAO Kristen Marie Williams sold 4,773 shares of the company’s stock in a transaction dated Tuesday, August 14th. The shares were sold at an average price of $47.04, for a total value of $224,521.92. Following the completion of the sale, the chief accounting officer now owns 22,374 shares of the company’s stock, valued at $1,052,472.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO David M. Stack sold 33,062 shares of the company’s stock in a transaction dated Wednesday, August 15th. The stock was sold at an average price of $47.32, for a total transaction of $1,564,493.84. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,502 shares of company stock valued at $1,913,864. Corporate insiders own 5.90% of the company’s stock.

A number of hedge funds have recently bought and sold shares of PCRX. US Bancorp DE lifted its holdings in Pacira Pharmaceuticals by 40.7% in the second quarter. US Bancorp DE now owns 6,038 shares of the company’s stock worth $194,000 after purchasing an additional 1,746 shares during the period. Cubist Systematic Strategies LLC lifted its holdings in Pacira Pharmaceuticals by 1,925.8% in the second quarter. Cubist Systematic Strategies LLC now owns 6,665 shares of the company’s stock worth $214,000 after purchasing an additional 6,336 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in Pacira Pharmaceuticals in the second quarter worth about $219,000. Bouchey Financial Group Ltd acquired a new stake in Pacira Pharmaceuticals in the third quarter worth about $221,000. Finally, Seven Eight Capital LP acquired a new stake in Pacira Pharmaceuticals in the third quarter worth about $308,000.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Recommended Story: How accurate is the Rule of 72?

The Fly

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.